Medication Package Insert for Methotrexate, Lederle. 1992. |
Giles et al., "A Platelet Release Defect Induced by Aspirin or Penicillin G Does Not Increase Gastrointestinal Blood Loss in Thrombocytopenic Rabbits," Haematology, vol. 57, No. 1, 1984, pp. 17-23. |
Bhagwatwar et al., "In Vitro and In Vivo Evaluations of Intravenous Busulfan Formulation," Pharmaceutical Research, vol. 10, No. 10, Oct. 1993, p. S190. |
Harshal et al., "Development of Intravenous Formulation of Busulfan," Pharmaceutical Research, vol. 9, No. 10, 1992, p. S200. |
J. E. F. Reynolds, "Busulfan," Martindale, The Extra Pharmacopoeia, 1989, The Pharmaceutical Press, London, pp. 603-604. |
Bhagwatwar, et al., "Formulation and Pharmacokinetics of Intravenous (I.V.) Busulphan," Proceedings of the American Association for Cancer Research, vol. 34, Mar. 1993, p. 269. |
Hagihara, Database WPI, Week 8916, Derwent Publications Ltd., London, GB; AN 89-117247 * JP, A, 1 061 429 8 Mar. 1989 see abstract. |
Andersson et al., "In Vitro and In Vivo Evaluations of Intravenous Busulfan Formulation," American Assoc. of Clinical Pharmacists, Annual Meeting, Nov. 1993. Abstract only. |
Bhagwatwar et al., "Formulation and Pharmacokinetics of Intravenous (I.V.) Busulphan (BU) in the Rat," American Association for Cancer Research, Orlando, Florida meeting, May 19-23, 1993. Abstract only. |
Blaise et al., "A Randomized Study OD CY-TBI vs BUS-CY+ALLO BMT for ANL in First CR: A Gegmo Study," BMT Suppl., 26, 1990, Abstract only. |
Buckner et al., "A Randomized Study Comparing Two Transplant Regimens for CML in Chronic Phase (CP)," Blood, 80(10) (Suppl. 1):277, 1992. Abstract only. |
Copelan et al., "Marrow Transplantation Following Busulfan and Cyclophosphamide for Chronic Myelogenous Leukaemia in Accelerated or Blastic Phase," British Journal of Haematology, 71:487-491, 1989. |
Giles et al., "A Platelet Release Defect Induced by Aspirin or Penicillin G Does Not Increase Gastrointestinal Blood Loss in Thrombocytopenic Rabbits," British Journal of Haematology, 57(1):17-23, 1984. Abstract only. |
Grochow et al., "Busulfan Disposition in Children," Blood, 75(8):1723-1727, 1990. |
Grochow et al., "Pharmacokinetics of Busulfan: Correlation with Veno-Occlusive Disease in Patients Undergoing Bone Marrow Transplantation," Cancer Chemotherapy and Pharmacology, 25:55-61, 1989. |
Hagenbeek, A., "Introduction of the BN Myelocytic Leukaemia," Leukemia Research, 1:85-90, 1977. |
Hagenbeek et al., "Proliferation Kinetics of the BNML Leukaemia In Vivo, " Leukemia Research, 1(2/3):99-101, 1977. |
Hassan et al., "Cerebrospinal Fluid and Plasma Concentrations of Busulfan During High-Dose Therapy," Bone Marrow Transplantation, 4:113-114, 1989. |
Hassan et al., "Pharmacokinetics of High-Dose Busulphan in Relation to Age and Chronopharmacology," Cancer Chemotherapy and Pharmacology, 28:130-134, 1991. |
Hassan et al., "In Vivo Distribution of [.sup.11 C]-Busulfan in Cynomolgus Monkey and in the Brain of a Human Patient," Cancer Chemotherapy and Pharmacology, 30:81-85, 1992. |
Hassan et al., "Pharmacokinetic and Metabolic Studies of High-Dose Busulphan in Adults," Eur. J. Clin. Pharmacol., 36:525-530, 1989. |
Lu et al., "Preliminary Results of High-Dose Busulfan and Cyclophosphamide with Syngeneic or Autologous Bone Marrow Rescue," Cancer Treatment Reports, 68 (5):711-717, 1984. |
Kitamura et al., "Anesthetic Management of Five Patients with Polycythemia Rubra Vera. Importance of Preoperative Managements," Jpn. J. Anesthesiol., 28(5):512-517, 1979. Abstract only. |
Miller et al., "A Randomized Trial of Busulfan-Cyclophosphamide (BU-CY) versus Cyclophamide-Total Body Irradiation (CY-TBI) as Preparative Regimen for Patients with Chronic Myelogenous Leukemia (CML)," Blood, 78:1155, 1991. Abstract only. |
"Methods of Development of New Anticancer Drugs," National Cancer Institute Monograph 45, pp. 147-153, Mar., 1977. |
Peters et al., "Clinical and Pharmacologic Effects of High Dose Single Agent Busulfan With Autologous Bone Marrow Support in the Treatment of Solid Tumors," Cancer Research, 47:6402-6406, 1987. |
Schwertfeger et al., "Early Toxicity of Busulfan/Cyclophosphamide versus TBI/Cyclophosphamide Conditioning for Allogeneic Bone Marrow Transplantation in Patients with Chronic Myelogenous Leukemia," Blood, 80(10) (Suppl. 1):2125, 1992. Abstract only. |
Sharkis and Santos, "Bone Marrow Transplantation in a BN Rat Model of Acute Myelogenous Leukemia (AML)," Leukemia Research, :251-252, 1977. |
Sheridan et al., "High-Dose Chemotherapy with Busulphan and Cyclophosphamide and Bone-Marrow Transplantation for Drug-Sensitive Malignancies in Adults: A Preliminary Report," The Medical Journal of Australia, 151:379-385, 1989. |
Tutschka and Santos, "Bone Marrow Transplantation in the Busulfan-Treated Rat," Transplantation, 20(2):101-106, 1975. |
Vassal et al., "Dose-Dependent Neurotoxicity of High-Dose Busulfan in Children: A Clinical and Pharmacological Study," Cancer Research, 50:6203-6207, 1990. |
Vassal et al., "Pharmacokinetics of High-Dose Busulfan in Children," Cancer Chemotherapy and Pharmacology, 24:386-390, 1989. |
Vaughan et al., "Improved Results of Allogeneic Bone Marrow Transplantation for Advanced Hematologic Malignancy Using Busulfan, Cyclophosphamide and Etoposide as Cytoreductive and Immunosuppressive Therapy," Bone Marrow Transplantation, 8:489-495, 1991. |
Dialog Search Report printed Mar. 31, 1993. |